Novel HCM therapy shows potential

The investigational therapy EDG-7500 was generally well-tolerated and improved several disease markers in patients with hypertrophic cardiomyopathy (HCM). The safety and efficacy of this agent will be explored further. EDG-7500 is an investigational cardiac sarcomere modulator tested in the open-label CIRRUS-HCM trial (NCT06347159) in patients with obstructive and non-obstructive HCM [1]. The 17 participants with obstructive HCM received 50 mg (n=8) or 100 mg (n=9) of the agent. In total, 89% of the participants in the 100 mg arm reached a resting left ventricular outflow tract (LVOT) <30 mmHg and 89% achieved Valsalva LVOT <50 mmHg. “These are clinically relevant results,” stated Dr Anjali Owens (University of Pennsylvania, PA, USA). Furthermore, 56% of the participants in the 100 mg arm reached an NT-proBNP <150 pg/mL. Dr Owens mentioned that there were also significant improveme...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 17 July 202521 July 2025